Resveratrol Attenuates the Release of Inflammatory Cytokines from Human Bronchial Smooth Muscle Cells Exposed to Lipoteichoic Acid in Chronic Obstructive Pulmonary Disease

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 2, 2014, Pages 202-209

  Knobloch, Jürgen ^a   Wahl, Chiara ^a   Feldmann, Maria ^a   Jungck, David ^a   Strauch, Justus ^a   Stoelben, Erich ^b   Koch, Andrea ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Lungenklinik Merheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LIPOTEICHOIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; RESVERATROL; TRICHOSTATIN A;

AGED; ARTICLE; BRONCHUS MUSCLE; CELL DEATH; CELL STIMULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAM POSITIVE INFECTION; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SMOOTH MUSCLE FIBER; SUPERNATANT;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

ADRENAL CORTEX HORMONES; AGED; ANTI-INFLAMMATORY AGENTS; CARBAZOLES; CHEMOKINE CCL2; CYTOKINES; DEXAMETHASONE; FEMALE; GRAM-POSITIVE BACTERIA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SIRTUIN 1; STILBENES; TEICHOIC ACIDS;

EID: 84891661882     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12129     Document Type: Article

References (46)

1. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546-56.
2. Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E, et al. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2010;335:788-98.
3. Koziol-White CJ, Panettieri RA Jr. Airway smooth muscle and immunomodulation in acute exacerbations of airway disease. Immunol Rev 2011;242:178-85.
4. Clarke D, Damera G, Sukkar MB, Tliba O. Transcriptional regulation of cytokine function in airway smooth muscle cells. Pulm Pharmacol Ther 2009;22:436-45.
5. Issa R, Sorrentino R, Sukkar MB, Sriskandan S, Chung KF, Mitchell JA. Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by gram-positive and gram-negative bacteria in human airway smooth muscle cells. Respir Res 2008;9:30.
6. Sukkar MB, Xie S, Khorasani NM, Kon OM, Stanbridge R, Issa R, et al. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 2006;118:641-8.
7. Zähringer U, Lindner B, Inamura S, Heine H, Alexander C. TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broadspecificity. Immunobiology 2008;213:205-24.
8. Edsbäcker S, Johansson CJ. Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Toxicol 2006;98:523-36.
9. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-17.
10. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease. JAMA 2013;309:2223-31.
11. Saha S, Siva R, Brightling CE, Pavord ID. COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition. Eur Respir J 2006;27:863-5.
12. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7.
13. Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:535-42.
14. Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003;58:942-6.
15. Ito K, Colley T, Mercado N. Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease. Int J Chron Obstruct Pulmon Dis 2012;7:641-52.
16. Knobloch J, Hag H, Jungck D, Urban K, Koch A. Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol 2011;109:138-43.
17. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Front Pharmacol 2012;3:141.
18. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-3.
19. Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008;66:591-6.
20. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006;203:7-13.
21. Knobloch J, Peters H, Jungck D, Müller K, Strauch J, Koch A. TNFalpha-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. Thorax 2009;64:1044-52.
22. Knobloch J, Lin Y, Konradi J, Jungck D, Behr J, Strauch J, et al. Inflammatory responses of airway smooth muscle cells and effects of endothelin receptor antagonism. Am J Respir Cell Mol Biol 2013;49:114-27.
23. Koch A, Giembycz M, Stirling RG, Lim S, Adcock I, Wassermann K, et al. Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages. Eur Respir J 2004;23:805-12.
24. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004;1:59-70.
25. Huhtiniemi T, Suuronen T, Rinne VM, Wittekindt C, Lahtela-Kakkonen M, Jarho E, et al. Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors. J Med Chem 2008;51:4377-80.
26. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, DiStefano PS, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006;26:28-38.
27. Stünkel W, Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen 2011;16:1153-69.
28. Jones P, Steinkühler C. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr Pharm Des 2008;14:545-61.
29. Watson PM, Riccio A. Nitric oxide and histone deacetylases: A new relationship between old molecules. Commun Integr Biol 2009;2:113.
30. Bengoechea JA, Ito K. Chronic obstructive pulmonary disease Th1 cells display impaired response to endotoxin. Am J Respir Crit Care Med 2011;183:148-50.
31. Knobloch J, Schild K, Jungck D, Urban K, Müller K, Schweda EK, et al. The T-helper cell type 1 immune response to gram-negative bacterial infections is impaired in COPD. Am J Respir Crit Care Med 2011;183:204-14.
32. Mat Z, Grensemann B, Yakin Y, Knobloch J, Koch A. Effect of lipoteichoic acid on IL-2 and IL-5 release from T lymphocytes in asthma and COPD. Int Immunopharmacol 2012;13:284-91.
33. Li XJ, Li Q, Si LY, Yuan QY. Bacteriological differences between COPD exacerbation and community-acquired pneumonia. Respir Care 2011;56:1818-24.
34. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007;2:191-204.
35. Schröder NW, Morath S, Alexander C, Hamann L, Hartung T, Zähringer U, et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003;278:15587-94.
36. Opitz B, Schröder NW, Spreitzer I, Michelsen KS, Kirschning CJ, Hallatschek W, et al. Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation. J Biol Chem 2001;276:22041-7.
37. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406-9.
38. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76.
39. Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:351-74.
40. Sharafkhaneh A, Velamuri S, Badmaev V, Lan C, Hanania N. The potential role of natural agents in treatment of airway inflammation. Ther Adv Respir Dis 2007;1:105-20.
41. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
42. Yang SR, Wright J, Bauter M, Seweryniak K, Kode A, Rahman I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol 2007;292:L567-76.
43. Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X, et al. Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts. PLoS ONE 2011;6:e27081.
44. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005;280:17187-95.
45. Hai CM. Airway smooth muscle cell as therapeutic target of inflammation. Curr Med Chem 2007;14:67-76.
46. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010;54:7-16.